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Many genes have been implicated in schizophrenia as have viral prenatal or adult infections and toxoplasmosis or Lyme disease.
Several autoantigens also target key pathology-related proteins. These factors are interrelated. Susceptibility genes encode for
proteins homologousto those of the pathogens while the autoantigens are homologousto pathogens’proteins, suggesting that the
risk-promoting eﬀects of genes and risk factors are conditional upon each other, and dependent upon protein matching between
pathogen and susceptibility gene products. Pathogens’ proteins may act as dummy ligands, decoy receptors, or via interactome
interference. Many such proteins are immunogenicsuggesting that antibody mediated knockdownofmultiple schizophrenia gene
products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and
the preponderance of immune-related gene variants in the schizophrenia genome. Schizophrenia may thus be a “pathogenetic”
autoimmunedisorder, caused by pathogens, genes, and the immune system acting together, and perhaps preventable by pathogen
elimination,or curable by the removal of culpable antibodies and antigens.
1.Introduction
Over 600 genes have been implicated in schizophrenia in
association studies, supporting the contention that multiple
genes of small eﬀect contribute to this condition [1, 2]( s e e
http://www.polygenicpathways.co.uk/schizgenesandfunc.htm
for association references). These genes cluster together in
clearly deﬁned signalling networks related to the diverse
subpathologies of schizophrenia [3–7]. Epistasis between
geneswithin these same signalling networks markedly aﬀects
t h ed e g r e eo fr i s k - p r o m o t i o n[ 8–10], in part, explaining the
inconsistency in genetic association studies.
Schizophrenia has also been associated with prenatal
complications including maternal rubella (German measles)
[11], inﬂuenza [12, 13], Varicella zoster (chicken pox) [14],
Herpes (HSV-2) [15], common cold infection with fever
[16], or poliovirus infection [17] while in childhood or
adulthood, coxsackie virus infection (in neonates [18]) or
Lyme disease (vectored by the Ixodes tick and Borrelia
Burgdorferri) or Toxoplasmosis have been reported as risk
factors [19, 20]( s e eTable 1). The human endogenous retro-
virus, HERV-W, has also been implicated in schizophrenia
[21].Anumberofschizophrenia-relatedgenesareimplicated
in the life cycles of these pathogens, suggesting an interplay
between genes and risk factors [22].
Many schizophrenia genes relate to the immune network
[5, 6, 22, 23]. Immune activation is also observed in the
schizophrenic brain [24, 25]o ri nl y m p h o c y t e s[ 26–29]. A
number of autoantigens/autoantibodies to key schizophre-
nia-related proteins have also been reported. These include
dopamine, serotonin, acetylcholine, and NMDA receptors;
inter alia (Table 2). Maternal immune activation in animal
models has also been shown to generate phenotypes relevant
to schizophrenia in the oﬀspring [30].
Asshown below,genes,riskfactors, andimmunitycanbe
linked together forming a unifying pathway whose elements
are interdependent. Dysfunction of this network which is
conditional upon interactions between its three branches
may be responsible for schizophrenia.2 Journal of Pathogens
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Figure 1: Screenshots of the pictorial representation ofthe viral BLAST results againstthe humanproteome. The streaks dotted throughout
the human genome/proteome represent the areas of homology, some with contiguous sequences of 5 or more amino acids. The number of
hits is shown for each virus or pathogen. The ﬁgure also shows the total coverage of human chromosome 10 by viral gene homologues. The
top set of ﬁgures were from unﬁltered blasts while the bottom set of 6 ﬁgures represent ﬁltered blasts using the query “schizophrenia”.4 Journal of Pathogens
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(c) The homology of viral risk factors to the highly antigenicregions of DISC1 (and of the viral homologues)
Figure 2: (a) Varicella protein alignments within DISC1: the boxed regions show the region of alignment, and the blue letters denote 100%
identity. This is not an alignment of the whole Varicella proteome but represents fragments of the same or diﬀerent Varicella proteins
that align with DISC1 fragments (vatches). The larger font delineates highly antigenic regions of DISC1 with an antigenicity index of >0.8
(Figure 4). (b) Other viral vatches within the DISC1 protein. The vatches are colour or format coded in relation to the diﬀerent viruses. (c)
Viral vatches for the risk factors implicated in schizophrenia in relation to the highly immunogenicregions of DISC1.
2.Methods
The human herpesvirus 2 genome (NC 001798) as well as
thoseoftherhinovirus (NC 001490),rubella(NC 001545.1)
and Varicella zoster (NC 001348.1) and HERV-W
(NP 055405.3: env polyprotein) viruses, Borrelia Burg-
dorferri (NC 011728) and T. Gondii (NC 001799: Partial
genome) were screened against the human proteome using
the NCBI BLAST server and the Entrez query ﬁlter
“schizophrenia”. The HERV-W,inﬂuenza, HSV-2 and rubella
viruses were also screened unﬁltered (Translated pathogen
genome versus human proteins: BlastX) [31]. The BLAST
algorithm detects overall homology between entire gene or
protein sequences, and it is necessary to set parameters to
low signiﬁcance levels in order to detect short intraprotein
consensus homology. The parameters used were: Expect
20,000, E value = 100,000; matrix PAM30. The original
BLAST results are stocked at http://www.polygenicpath-
ways.co.uk/blasts.htm. Information for all abbreviations is
available at this site, provided by the NextBio highlighting
service.
BLAST ﬁles were scanned by an online tag cloud
generator producing tags sized according to gene
word occurrences http://www.tagcloud-generator.com/
generator.php#anker. Word occurrences were counted
using a “Highlightall add-in” for Firefox https://addons
.mozilla.org/en-US/ﬁrefox/addon/4240/.
Antigenicity (B-cell epitope prediction) was estimated
using the BepiPred server http://www.cbs.dtu.dk/services/
BepiPred/[32]( Table 4).
Kegg pathway analysis [33] of 632 schizophrenia suscep-
tibility gene candidates was performed using Kegg mapper
http://www.genome.jp/kegg/tool/color pathway.html.T h e
results of this analysis are available at http://www
.polygenicpathways.co.uk/keggszgenes.htm.V e n nd i a g r a m s
were constructed online at http://www.bioinformatics.org/
gvenn/index.htm[34].
Genes and risk factors with at least one positive asso-
ciation are included in this study. Although certain genes
and risk factors are clearly more important than others, and
problems of replication in both gene and risk factor studies
abound, gene, gene, and gene/environment interactions
may explain some of the heterogeneity. For example many
schizophrenia-related genes are involved in the life cycle of
T. Gondii, but may be irrelevant if this pathogen is not
encountered. Similarly T. Gondii infection may have little
eﬀect is such gene variants are not present. Pathway analyses
of genome wide association data, and previous studies, are
showing that the risk-promoting eﬀects of many genes in
similar pathways are better predictors of risk, than when
treating each gene in isolation (see Section 1). Although
some of these factors may be false positives, many genes and
risk factors may have a role to play in certain conditions, but
the greater import of genes such as DISC1 or neuregulin is
recognised.
3.Results
Pictograms of selected BLAST results are shown in Figure 1.
TheinitialsweepofunﬁlteredBLASTsreturned125–304hits,
but this number was markedly increased when using the
ﬁlter“schizophrenia” (14,088HitsforHSV-2).Forunﬁltered
sweeps, the viral homologues are longer, while the ﬁltered
sweeps return shorter contiguous sequences nevertheless
including multiple matches of pentapeptides or more.
Viral-human matches are characterised by short con-
tiguous amino acid matches of 5 or more amino acids,
that are identical in viral and human proteins, deﬁned as
vatches (viral matches). These are exempliﬁed, for DISC1
in Figure 2. Hexapeptide matches have also been described
for the inﬂuenza H5N1 virus and this study also highlighted
homologies with DISC1, reelin and neurexin, inter alia [35].
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Figure 3: (a) Venn diagrams of the number of Schizophrenia gene products (N = 632) with homology to the rubella, HERV-W and
inﬂuenza viruses. The singleton in SZ-genes was diﬀerent on each occasion: Thus, all genes are covered. (b) The viral matching spectra of
DISC1,neuregulin, thedopamineD2 receptor andtranscriptionfactor4.The Y-axisdepicts thenumberofwordoccurrences ontheoriginal
BLAST results page. Note the logarithmic axis. (c) The number of pathogens expressing proteins with homology to the protein products of
schizophrenia susceptibility genes. Those marked by an asterisk are within the 30 top-ranked genes in SZ-gene http://www.szgene.org/.Journal of Pathogens 9
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Figure 4: Theantigenicity(B-cell epitope prediction) ofDISC1:theaminoacidsequences withanindex of >0.35are considered asepitopes.
A value of 0.8 was chosen to deﬁne highly antigenic regions as seen in Figure 2. The amino acid sequences of these highly antigenic regions
are shown.
many overlapping, intercalated vatches, related to multiple
v i r a ls p e c i e s .H o w e v e r ,t h ev i r a ls p e c t r u mi sd i s t i n c tf o re a c h
protein as shown in Figure 3 for DISC1, neuregulin, the
D2 dopamine receptor and transcription factor 4. Each is
homologoustoproteinsfromalargespectrumofviruses, but
thisspectrum is distinctfor eachprotein.Interestingly, all are
homologous to proteins from the hepatitis C virus. Several
studies have noted that Hepatitis C infection is associated
with schizophrenia, but this has generally been interpreted
in terms of a schizophrenia life style that favours infection,
rather than viewing Hepatitis C as a risk-promoting factor
[36–39]. These data may challenge this assumption.
All of the pathogens implicated in schizophrenia express
proteins with homology to multiple schizophrenia suscepti-
bility gene products (Table 3). The proﬁle of each individual
pathogen is again speciﬁc for diﬀerenttypes ofgene product,
but all target key members of the schizophrenia network
including dopamine, serotonin and glutamate receptors as
well as neuregulin and growth-related or DISC1 related
pathways. This is the case even when no ﬁlter is used. Inter-
estingly, both the rubella and the inﬂuenza viruses target
members of the translation initiation complex, which has
beenimplicated in myelination andoligodendrocytesurvival
[4, 40]. Oligodendrocytecell loss and myelination defectsare
prominent in the schizophrenic brain [41–44].
The degree of overlap between the rubella, HERV and
inﬂuenza viruses and schizophrenia gene products is shown
by the Venn diagrams in Figure 3.A l lb u to n es c h i z o p h r e -
nia gene product was covered by various permutations
and similar data were recovered for other pathogens. All
schizophrenia gene products (N = 632) were homologous
to proteins expressed by one or more of these pathogens.
However, only 16 proteins were common to all 8 pathogens
(Figure 3). These included neuregulin (NRG1) and DISC1,
dopamine (DRD5), glutamate (GRIA4, GRID1, GRM3,
GRM7) GABA (GABBR1) and serotonin (HTR7) receptors,
a presynaptic protein regulating glutamate release (synapsin
SYN3)andHOMER2,amemberofthepostsynapticscaﬀold,
all of which are key elements relating to the pathology of
schizophrenia.
Other proteins within this class included neurocan
(CSPG5), a chondroitin sulphate proteoglycan expressed in
oligodendrocytes that inhibits neurite outgrowth and reg-
ulates axonal growth [45–47]. It is also involved thalamo-
cortical projection development [48]. ARHGEF10 is a rho
Guanine-nucleotide exchange factor that controls myelina-
tion[49].NDUFV2isasubunitofthemitochondrialrespira-
tory chain and itsprotein expression levelsare reduced in the
frontal cortex and striatum in schizophrenia [50]. PPP3CC
Calcineurin gamma (PPP3CC) plays a role in dopamine
receptor signalling [51,52].Calcineurinknockoutmiceshow
defects in prepulse inhibition and other phenotypes related
to schizophrenia [53]. Calcineurin is highly expressed in the
immune system and regulates the expression of numerous10 Journal of Pathogens
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Figure 5: The DISC1 interactome see http://www.polygenicpathways.co.uk/discforum.htm. Proteins in red are homologous to Rubella
proteins.
cytokines [54]. MAP6 is a microtubule protein that con-
trols synaptic organisation, in particular of glutamatergic
synapses where it controls the expression of the glutamate
transporter and presynaptic genes, synaptophysin and GAP-
43, spinophilin and MAP2. [55, 56] KCNH2 is a potassium
channel that plays a role in the development of neural crest
cells [57] and in lymphocyte proliferation [58]. PRSS16 is
a serine protease involved in autoimmunity and the presen-
tation of self-antigens within the thymus [59].
So, by a random bioinformatics process, trawling the
entire human proteome, asking simply which proteins are
homologous to those of the pathogens implicated in schiz-
ophrenia, we arrive at a small set of proteins related to
synapticanddendriticfunction,myelination,neuregulinand
DISC1pathways,glutamate,dopamine,GABAandserotonin
transmission, and immune regulation that are the corner-
stones of schizophrenia pathology [3, 60–62].
3.1. Autoantigens in Schizophrenia. Many autoantibodies
have been reported in schizophrenia. The pathogens impli-
cated in schizophrenia also express proteins that are homol-
ogous to these autoantigens. Again the proﬁle of each
autoantigen or pathogen is distinct as shown in Table 2.
3.2. DISC1. DISC1 is a key “hub gene” in schizophrenia
linked, via its interactome, to many other schizophrenia
susceptibility gene products [3, 63–66]. Its viral homology
is illustrated in Figure 2. The Varicella virus is homologous
to DISC1 in several regions, over its entire length, many
matches in regions of high immunogenicity. These ﬁgures
illustrate the types of matches seen in other proteins and
shows that the vatches are often part of larger gapped
consensus sequences. Interestingly, Varicella infection also
results in the production of antibodies to pericentrin,
aD I S C 1 b i n d i n g p a r t n e r [ 67].
DISC1 is a highly immunogenic protein, as predicted by
B-cell epitope prediction (Figure 4). Autoantibodies to
DISC1 have not been reported in schizophrenia. However,
the viral risk factors implicated in schizophrenia express
proteins that are homologous to the highly antigenic regions
of the DISC1 protein, as shown in Figure 2.T h e s ev i r a l
proteins are equally antigenic and antiviral antibodies might
also thus be expected to target multiple regions of the DISC1
protein.
3.3. Viral Proteins Are Part of the DISC1 Interactome. DISC1
and many of its binding partners, or other members ofJournal of Pathogens 11
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Figure 6: A screen shot of the HSV-2 BLAST results using the ﬁlter “dopamine receptor”. The repeated patterns correspond to dopamine
receptors on diﬀerent chromosomes as shown in Table 1. Homology with glutamate, serotonin, GABA, acetylcholine and other receptors is
also noted.
its interactome, contain vatches that are homologous to
proteins expressed by the Rubella virus (Figure 5). (Other
viruses also display this property, although the interactome
memberstargetedaredistinct,andspeciﬁcforeachvirus(see
http://www) .polygenicpathways.co.uk/vatches.htm). Upon
infection, viruses might therefore be considered as extrane-
ous spurs to these types of protein/protein networks, and
are likely to markedly aﬀect their integrity. Indeed, several
viruses, including herpes simplex, hepatitis C, Epstein-Barr,
the cytomegalovirus, adenovirus and Coxsackie virus are
known to bind to DISC1 interaction partners (Table 4).
3.4. Viral DNA within the Human Genome. The insertion of
viral DNA into the human genome had until recently
been thought to be the preserve of retroviruses. However
the incorporation of DNA into mammalian genomes has
recently been demonstrated on a large scale for both RNA
and DNA viruses. Viral integration may be mediated by
nonhomologous recombination with chromosomal DNA
or, in the case of RNA viruses, by interactions with host
chromosomal retrotransposons [68, 69]. It has also been
shown the herpes virus HHV-6 can be transmitted from
parent to child via chromosomal integration [70]. The12 Journal of Pathogens
BLAST analyses of the viruses detailed in this paper, and
of others at http://www.polygenicpathways.co.uk/blasts.htm
clearly show that viral DNA from many species is present
within the human genome. This viral homology may well
cover the entire human genome. For example, a Blast of
human chromosome 10 against all viral genomes (almost
3,000 viral forms) yielded 119,857 hits with entire coverage
of 135.5 million bases. Viral DNA is thus both inter and
intragenic (Figure 1). It has been proposed that retroviral
integration, into paternal and maternal gene lines, inserting
several genes at once and eﬀectively creating a new being, is
responsibleforevolutionarysaccades[71].ThefactthatRN A
and DNA nonretroviruses can also be so incorporated has
important implications in this area.
The HSV-2 virus is homologous to several dopamine
receptors and the BLAST pictogram shows how the same
virus provokes repeating patterns in the human pro-
teome (Figure 6) .T h es a m ei st r u eo ft h eH e r p e ss i m -
plex virus (HSV-1) which is homologous to multiple
lipoprotein receptors as well as to multiple kinases or
of the cytomegalovirus which expresses proteins homol-
ogous to many chemokine receptors (see http://www
.polygenicpathways.co.uk/blasts.htm). One interpretation of
this, given the ability of chromosomal integration, is that
repeated viral visits to the human genome over millions of
years are responsible for the creation of gene families.
It is also possible that viral/human homology reﬂects
convergent viral evolution, although this is diﬃcult to rec-
oncile with the presence of viral DNA in intergenic regions,
for which there would be little evolutionarydrive or selective
pressure. It is also plausible that a bidirectional transfer of
human and viral DNA could be at work.
F o rw h a t e v e rr e a s o n ,t h er e s u l ti st h a th u m a np r o t e i n s
resemble those expressed by a multitude of today’s viruses
and other pathogens. Upon infection, these pathogens are
thus able to interfere with the function of their human
counterparts in a number of ways (see below).
3.5. Copy Number Variations and the Eﬀects of Parental Age
on Risk. Repeated viral insertion could well explain copy
number variations, which are associated with a number of
diseases, including schizophrenia [72, 73]. As their number
increases, so will the number of matches to the same viral
proteins, thus increasing the risk of viral interference and
autoimmunity. As viral infection can be passed from parent
to child via chromosomal integration, perhaps this is also
whybothpaternalandmaternalolderagehavebeenreported
as risk factors in schizophrenia and other disorders [74, 75].
3.6. KEGG Pathway Analysis of Schizophrenia Susceptibility
Genes. The color-codedpathwaysfor this analysis are posted
at http://www.polygenicpathways.co.uk/keggszgenes.htm.I t
conﬁrmed the involvement of a number of polygenic path-
ways, including long-term potentiation and oxidative stress
[3] growth factor/neuregulin pathways [121], neuroactive
ligandpathways(dopamine/serotonin/glutamateandothers)
as well as dopamine metabolism pathways[9]. In the context
of this review, a large number of immune-related pathways
are traced out by these genes, together with many pathogen-
related pathways, including toxoplasmosis, which heads the
list(Table 5).Theinvolvementofschizophrenia relatedgenes
in the life cycles of pathogens has been the subject of
ap r e v i o u sr e v i e w[ 22] and this relationship is supported by
this analysis. Other pathogen related pathways relating to
amoebiasis, Staphylococcus aureus and Helicobacter pylori
infection, might indicate the involvementof other pathogens
in schizophrenia, although such pathways could also be con-
sidered as generic pathways related to many pathogens.
T h e r ei sn os p e c i ﬁ cv i r a ll i f ec y c l ep a t h w a yw i t h i nt h e
KEGG dataset. However, viruses use adhesion molecules as
receptors, endocytosis for cellular entry and the intracellular
actin and tubulin networks for migration to and from the
nucleus, mediated via dynein and kinesin motors. They also
subjugateintracellular vesiculartraﬃckingpathways, andare
able to subvert both lysosomal and phagosomal pathways.
Their exit may depend upon exocytosis, or by apoptotic or
other means of killing their host cell [122]. These pathways
are heavily represented within the schizophrenia gene analy-
sis.
3.7. Mechanisms of Action. Individual proteins are homol-
ogous to multiple viral proteins, which nevertheless are
speciﬁcforaspectrumofviruses,while individualvirusesare
homologous to a large butspeciﬁc subset of human proteins.
Our proteomes therefore contain proteins with sequen-
ces exactly matching those in the current virome, and in
the proteomes of bacteria and other pathogens, which are
also subject to phage or viral infection. Pathogens’ proteins
are therefore homologous to receptors, transporters, peptide
messengers, growth factors, and other protein products of
diverse gene families. Upon infection, surrogate dopamine,
NMDA serotonin and other receptors, as well as transporters
and enzymes are made available, which in eﬀect may steal
the ligands of their human counterparts. It is already known
that the dopaminergic ligand, amantadine, binds to the
inﬂuenza virus [123], which expresses proteins homologous
to dopamine receptors (Table 3). When homologous to pep-
tide ligands, viral proteins may occupy and block or perhaps
stimulate their cognate receptors, or use them for entry, as
is the case with the AIDS virus and the CCR5 and CXCR4
chemokine receptors [124].
This is illustrated by the Norovirus (Norwalk) which
causes vomiting sickness. The virus expresses proteins
homologoustomonoamine andotheramineoxidasesaswell
as to a number of dopamine and monoamine transporters
(Table 6). Dopamine subversion by the viral homologues
would be expected to increase dopamine levels resulting in
emesis, thus explaining the recurrent vomiting produced by
infection.
The potentialinterference byviruseswithin protein/pro-
tein networks is well illustrated by the homology of rubella
proteinstoDISC1andothermembersofitsinteractome,and
by the fact that many viruses have indeed been found to bind
to these components (Table 4).
The homologous human proteins of the viral risk factors
implicated in schizophrenia correspond to the genomicJournal of Pathogens 13
Table 1: Some of the pathogens implicated in Schizophrenia, either in relation to maternal infection, or to infection in later life.
Pre- and perinatal maternal infection Juvenile (in oﬀspring) Adult
Rubella (ﬁrst trimester) [76]:
Inﬂuenza (ﬁrst trimester) [13]
Inﬂuenza or commoncold with fever
(second trimester) [16]
Mumps or cytomegalovirus infection
(0–12 years old) [77]
HSV-1 seropositivity related to grey matter
volume [78]
Poliovirus (second trimester) [17] Coxsackie B5 infection perinatally [18]
HSV-1 (in Afro-Americans) or HHV-6
seropositivity: Inverse correlation with HSV-2
and cytomegalovirus [79]
Measles, Varicella zoster or polio
(seropositivity at birth) [14] Childhood meningitis (0–4 years old) [80] Borna disease virus seropositivty [81]
HSV-2 (antibodies assayed at the end of
pregnancy) [82] Coronavirus seropositivity [83]
Inﬂuenza B (seropositivity at birth) [84] Elevated retrovirus HERV-W transcripts [85]
Toxoplasmosis(antibodies during
pregnancy) [86] Measles virus seropositivity [87]
Hepatitis C [38]
Toxoplasmosis [88]
Correlation with the incidence of Lyme disease
(Borrelia) [20]
Table 2: Pathogens expressing proteins with homology to the autoantigens reported in schizophrenia. The size of the tags is proportional
the number of pathogen’s proteins that are homologousto the autoantigen. Note that the proﬁle is diﬀerent for each pathogen. The original
BLAST ﬁles can be found at http://www.polygenicpathways.co.uk/blasts.htm.
Autoantigen reference Pathogens
CHRNA7 Nicotinic cholinergic receptor [89]
CHRM1 Muscarinic cholinergic receptor [90]
DRD2 Dopamine receptor [82]
GRIN1 NMDA receptor subunit [91]
ELANE Leukocyte elastase [92]
OPRM1 Opioid receptor [93]
NGF Nerve growth factor [92]
HTR1A Serotonin receptor [93]
HSP60 Heat shock protein 60 [94]
HSPA12A Heat shock protein 70 [95]
HSP90 Heat shock protein 90 [95]
PAM/MYC [94]
S100B [96]
STRN Striatin [96]
locations of 632 schizophrenia susceptibility genes (see Venn
diagrams). Both negative and positive genetic association
results have been reported for these many genes and it now
seems plausible that, in some cases, this may be due to
the presence or absence of active infection with these and
other pathogens, and that DNA assays have been detecting
pathogen as well as human DNA in the blood samples used
for assay. There is evidently no way of discriminating viral or
bacterial double-stranded DNA from human DNA.
This is not speciﬁc to schizophrenia, as the viruses impli-
cated in Alzheimer’s disease (HSV-1, HIV-1, HHV-6 and
the cytomegalovirus) [125–127] are also homologous to
proteins encoded by Alzheimer’s disease susceptibility genes
see http://www.polygenicpathways.co.uk/blasts.htm [128].
It seems that a viable interpretation, given the same
phenomenon in these diseases, is that these genes are sus-
ceptibility genes precisely because they encode for proteins
withhomologytotheviralriskfactors.Infectionandgenetics14 Journal of Pathogens
Table 3: Human proteins with homologyto proteins expressed by pathogens.The size of the tags reﬂects the number of pathogen’s proteins
that are homologous to the human protein: the ﬁlters used are described. The number of schizophrenia susceptibility genes within each of
these datasets is shown in the left-hand column. Certain genes are classiﬁed according to family and are highlighted in red. Gene deﬁnitions
and the original BLAST ﬁles can be found at http://www.polygenicpathways.co.uk/blasts.htm. Note that the homologues are often clustered
in families (e.g., HTR1A, HTR2A, HTR3A, HTR3B, HTR3E, HTR5A, and HTR7).Journal of Pathogens 15
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therefore appear to be interdependent. The pathogens may
promote disease if the human genes encode for homologous
products, and the genes promote disease if the homolo-
gous pathogen is encountered. Such interdependence likely
explains the heterogeneous data in both gene and risk factor
association studies.
Other pathogens, including Borrelia Burgdorferri and T.
Gondii have also been implicated in schizophrenia. These
too express many homologous proteins to both viral and
human proteomes. These parasites tend to be associated
with schizophrenia in adulthood, while viral infections are
predominantly prenatal risk factors. These may have primed
the antibody network to respond to homologous antigens
expressed by Borrelia or T. Gondii, suggesting that detection
and elimination of these pathogens may be of therapeutic
beneﬁt in adult life.
Schizophrenia is a neurodevelopmental disorder [129,
130] and, as the risk-promoting eﬀects of viruses are related
to maternal infection, it is possible that knockdown or
interference of foetal proteins by viral-induced antibodies
targeting their human counterparts may contribute to the
neurodevelopmental disturbances observed in schizophre-
nia. Indeed DISC1, neuregulin, ERBB4, FEZ1 or COMT
knockout mice display many of the pathological and
behavioural symptoms associated with schizophrenia [131–
135]. Viral interference with these same proteins might be
expected to promote the same eﬀects, but on a massive
scale, targeting many relevant proteins at once. It is also
possible that such autoantibodies play a role in the comor-
bid conditions associated with schizophrenia, for example
autoimmune disease such as Thyrotoxicosis, celiac disease,
acquiredhaemolyticanaemia,interstitial cystitis,orSjogren’s
syndrome [136].
Autoantibodies to several proteins have been reported
in schizophrenia (muscarinic, nicotinic, dopaminergic and
NMDAreceptors,interalia,( Table 2)andallarehomologous30 Journal of Pathogens
Table 4: Viruses reported to bind to DISC1 interactome partners.
DISC1 partner
gene symbol Protein name Viral binder
ACTG1 Actin, cytoplasmic 2 HIV-1 [97]H S V 1[ 98]
ACTN2 Actinin, alpha 2 Hepatitis C [99]
AKAP9 A-kinase anchor protein 9 Epstein-Barr [97]
ATF4 Cyclic AMP-dependent transcription factor ATF-4 HSV1 [98]
ATF5 Cyclic AMP-dependent transcription factor ATF-5 HTLV1 [100]
BICD1 Protein bicaudal D homolog1 Cytomegalovirus [101]
C14orf135 Uncharacterized protein C14orf135 precursor Hepatitis C [102]
DCTN1 Dynactin-1 HSV1 [98]
DCTN2 Dynactin subunit 2
Dynactins are involved in the transport of the
adenoviruses, HSV-1, the hantaanvirus, HTLV-1
and the poliovirus [103–108]
DNAJC7 DnaJ homolog subfamily C member 7 Part of a complex forming the coxsackievirus
receptor [109]
DYNC1H1 Dynein heavy chain, cytosolic Adenovirus (in a complex with dynactin and
NDEL1) [110]
EEF2 Elongation factor 2 Epstein Barr [111]
EIF3S3 Eukaryotic translationinitiation factor 3 subunit 3 Hepatitis C [112]
FEZ1 Fasciculation and elongation protein zeta 1 (zygin I) JC Polyomavirus[113]
HERC2 HECT domainand RCC1-like domain-containingprotein 2 Papillomavirus 16 [114]
KIF3C Kinesin-like protein KIF3C HIV-1 [115]
MATR3 Matrin-3 HSV1 [98]
NDEL1 Nuclear distribution protein nudE-like 1 Part of a complex involved in Adenovirus transport
(with dynactin and cytoplasmic dynein) [110]
PAFAH1B1 Platelet-activating factor acetylhydrolase IB subunit alpha B i n d st oP o l i o v i r u sP 3p r o t e i na n dH I V - 1T a t
[116, 117]
PCNT Pericentrin Involved in the microtubular transport of the
adenovirus [118]
PGK1 Phosphoglycerate kinase 1 Epstein-Barr [119]
SMARCE1 SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily E member 1 HSV-1 [97]
STX18 Syntaxin-18 Papillomavirus [119]
TNKS Tankyrase-1 Epstein-Barr [120]
TUBB Tubulin beta chain Epstein-Barr [119]
YWHAE 14-3-3 protein epsilon Hepatitis C [97]: L:Epstein-Barr[119]
YWHAQ 14-3-3 protein theta HIV [97]H S V 1[ 98]
YWHAZ 14-3-3 protein zeta/delta HSV1 [98]:Epstein-Barr[119]Journal of Pathogens 31
Table 5: The number of schizophrenia gene products in KEGG pathways related to immunity, and viral or pathogen life cycles.
Pathogen pathways Viral pathways Immune
Toxoplasmosis 16 Focal adhesion 20 Cytokine-cytokine receptor
interaction 26
Chagas disease 15 Cell adhesion molecules
(CAMs) 19 Jak-STAT signalingpathway 16
Amoebiasis 13 Regulation of actin
cytoskeleton 17 Systemic lupus erythematosus 13
Leishmaniasis 12 Protein processing in
endoplasmic reticulum 13 T cell receptor signaling
pathway 13
Viral myocarditis 8 Endocytosis 12 Phagosome 12
Staphylococcus aureus
infection 7 Phagosome 12 Allograft rejection 11
Epithelial cell signaling in
Helicobacter pylori infection 6 Gap junction 11 Hematopoietic cell lineage 11
Malaria 6 Tight junction 11 Antigen processing and
presentation 10
Tryptophan metabolism 6 Adherens junction 6 Fc epsilon RI signaling
pathway 10
NOD-like receptor signaling
pathway 4 ECM-receptor interaction 6 Apoptosis 10
Vibrio cholerae infection 4 Oocyte meiosis 5 Graft-versus-host disease 9
Bacterial invasion of epithelial
cells 3 SNARE interactions in
vesicular transport 4 Autoimmune thyroid disease 8
E.coli infection 3 Chemokine signaling pathway 8
RIG-I-like receptor signaling
pathway 3 Basaltranscription factors 3 Leukocyte transendothelial
migration 8
Cytosolic DNA-sensing
pathway 2S p l i c e o s o m e 2Natural killer cell mediated
cytotoxicity 8
Shigellosis 2 Aminoacyl-tRNA biosynthesis 1 Adipocytokine signaling
pathway 7
Base excision repair 1 Asthma 7
RNA degradation 1 Intestinal IgA production 5
Toll-like receptor signaling
pathway 5
Complement and coagulation
cascades 4
B cell receptor signaling
pathway 3
TGF-beta signalingpathway 3
Lysosome 2
Regulation of autophagy 2
Fc gamma R-mediated
phagocytosis 1
Primary immunodeﬁciency 1
toproteinsexpressedbytheriskfactorsinschizophrenia.The
eﬀects of antibody knockdown have not been analysed for
any schizophrenia related proteins, but have been reported
for the microtubule-related protein tau,i nr e l a t i o nt oA l z -
heimer’s disease. In mice, tau immunisation produces tau
hyperphosphorylation, neuroﬁbrillary tangles and axonal
damage as seen in the human condition [137]. Tau (MAPT)
is homologous to Herpes simplex (HSV-1) and a number of
otherpathogens.Sucheﬀectsare relevanttotheautoantigens
observed in schizophrenia.
Schizophrenia is also a degenerative disease in adoles-
cence or adulthood, characterised by oligodendrocyte cell
loss, impaired synaptic connectivity and pyramidal cell den-
drite shrinkage [41, 138–140], In the light of the above
homologies it seems likely that such degenerative changes
may relate to autoimmune-related attack of these diverse
compartments. Indeed there is evidence for microglial acti-
vation in the schizophrenic brain [141] and several studies
have reported changes in the cytokine proﬁle in the brain,
CSF or peripheral immune compartments [24, 142–146].32 Journal of Pathogens
Table 6: Human homologues of Norwalk virus proteins.
Dopamine metabolisers Amine transporters Others
AOC2 amine oxidases
AOC3“”
KDM1Aamine oxidase demethylase
KDM1B“”
MAOAmonoamineoxidase
MAOB“”
RNLS renalase amine oxidase
SMOX spermine oxidase
SPR sepiapterin reductase
Monoamine synthesis cofactor
SULT1A1sulphotransferases
SULT1A3monoamine metabolite
sulphation
SULT1A4
SLC6A2 (Noradrenaline)
SLC6A3 (Dopamine)
SLC18A1vesicularmonoamine
SLC18A2“”
SLC22A2 organiccation
SLC22A3 extraneuronalmonoamine
SLC29A4 (Na+/H+)
CADPS2amine release activator
CDCA7 cell divisioncycle associated 7
CDCA7L
IL4I1 cytokine
PICK1 postsynaptic scaﬀold
3.8. Clinical Implications in Schizophrenia and Other Condi-
tions. These data suggest that susceptibility gene products
are the vehicles enabling the risk-promoting eﬀects of
pathogenic risk factors, via the interactions described above,
and that the two are indispensable for the genesis of schizo-
phrenia. Pathogen detection and elimination or vaccination,
particularly prior to pregnancy might be expected to reduce
the incidence of schizophrenia and also to be of clinical
beneﬁt in adulthood. Interestingly, vitamin D is able to stunt
the growth of T. Gondii [147] and low levels of this vitamin,
both prenatally and in adulthood, have been associated with
schizophreniarisk,althoughabnormallyhighlevelsarealsoa
risk factor [148]. Pharmaceutical eﬀort in this direction may
also vastly improve the armoury and safety of drugs against
parasites such as T. Gondii and Borrelia.
Autoimmunity, involving several key schizophrenia-
related proteins may well be a consequence of pathogen
infection, and related to viral/human protein homology.
Antigen and antibody removal by immunoadsorption tech-
niques might therefore also be if clinical beneﬁt.
This scenario suggests a novel and probably common
class of “pathogenetic” autoimmune disease caused by path-
ogens but dependent on our genes. Indeed, the same phe-
nomenon has been observed in Alzheimer’s disease where
the risk factor herpes simplex expresses proteins contain-
ing peptide matches to the products of multiple sus-
ceptibility genes [128]. Work from Kanduc’s laboratory
has also shown that 30 viral proteomes, including many
nonretroviruses, contain multiple pentapeptide matches to
many human proteins [149]. This is corroborated by data
posted at http://www.polygenicpathways.co.uk/blasts.htm
which shows, inter alia, that Bornavirus proteins, a virus
implicated in Bipolar disorder [150], display this type of
homology in relation to Bipolar disorder susceptibility gene
products, that the coronavirus implicated in Parkinson’s
disease [151] expresses proteins homologous to the PARK7
gene product and to dopaminergic and oxidative stress-
related proteins, and that multiple sclerosis autoantigens are
homologous to the products of the Epstein-Barr virus which
has been implicated in this disorder [152]. Our genomes and
polymorphisms determine which vatches we possess, which
pathogens match these sequences and which pathogen-
related disorder we might develop. Environmental variables,
and vaccination, determine which pathogens we encounter
and our immune system (HLA-antigens and immune back-
ground determined soon after birth) may determine how we
deal with these pathogens. With the power of current day
bioinformatics, it should be possible to rapidly identify all
vatches in the human proteome and to pair them with
the various pathogenic species and human diseases. This
would greatly aid our understanding of the implication of
pathogens in disease and may lead to radically new therapies
and prevention strategies in many disorders.
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